Get the Stockscreener App
16.58
4.08%
0.65
After Hours:
17.00
0.42
+2.53%
Immunic Inc stock is traded at $16.58, with a volume of 165.42K.
It is up +4.08% in the last 24 hours and up +13.25% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$15.93
Open:
$16.07
24h Volume:
165.42K
Relative Volume:
0.83
Market Cap:
$226.23M
Revenue:
-
Net Income/Loss:
$-104.29M
P/E Ratio:
-2.7483
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
+14.03%
1M Performance:
+13.25%
6M Performance:
+81.70%
1Y Performance:
+99.93%
1-Day Range:
$15.70
$16.86
1-Week Range:
$13.79
$16.86
52-Week Range:
$5.062
$16.86
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
16.58 | 217.36M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - zacks.com
Immunic (IMUX) sees Soleus Capital group disclose 4.9% beneficial stake - Stock Titan
Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100 - GuruFocus
Small cap wrap: 1911 Gold, Dune Oil, Nextech3D.ai, C3 Metals, Immunic… - ca.proactiveinvestors.com
Immunic Releases Q2 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Immunic Inc For: 11 August By Investing.com - Investing.com Nigeria
Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS - MarketBeat
Immunic Appoints Biopharma Finance Veteran Elena Ridloff to Board of Directors - Minichart
Immunic Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Immunic advances MS drug vidofludimus calcium t... - Pluang
Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program - Bitget
Immunic advances MS drug trials, expects Phase 3 data by end 2026 and plans NDA filing in 2027 - Pluang
Immunic Inc (IMUX) Q2 Earnings Beat Highlights Growth Potential Despite Unprofitability - GuruFocus
Immunic appoints Elena Ridloff to board ahead of Phase 3 MS readout - Quiver Quantitative
Immunic (IMUX) Advances Clinical Stage, Market Eyes Growth Despi - GuruFocus
Immunic: Q2 Earnings Snapshot - AOL.com
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Immunic advances MS drug toward key Phase 3 data, expects results by year-end - Proactive financial news
Immunic files Form 3 for director Elena Ridloff, reporting no beneficial ownership - Bitget
Immunic (IMUX) director Elena Ridloff receives 50,740 stock options at $14.54 - Stock Titan
Immunic appoints Elena Ridloff to board of directors By Investing.com - Investing.com Nigeria
Immunic Appoints Elena Ridloff to Board of Directors - PR Newswire
Immunic CEO on Q2 progress and Phase 3 MS trial milestones - Yahoo Finance
Immunic appoints Elena Ridloff to board of directors - Proactive financial news
Immunic Inc (NASDAQ: IMUX) Share Price, IMUX Stock News, IMUX Share Price & Updates - kalkine.ca
Millennium entities (IMUX) disclose 7.0% beneficial ownership in Immunic common stock - Stock Titan
Immunic Inc (IMUX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Laurion Capital discloses 6.06% Immunic (IMUX) stake via shares and warrants - Stock Titan
Immunic Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
OMERS ADMINISTRATION Corp Makes New Investment in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunic Inc (IMUX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMUX|Immunic Inc|Price:13.390|Chg%:-0.890 - TradingKey
IMUX|Immunic Inc|Price:13.970| - TradingKey
Immunic Inc (IMUX) Cash Flow - TradingKey
TradingKey - TradingKey
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic, Inc. Revenue Breakdown – NASDAQ:IMUX - TradingView
Immunic Inc. (IMUX) Edges Higher as Support HoldsStock Buy Zone - dars.gov.et
Immunic Inc. (IMUX) Edges Higher Amid Steady Trading: Key Levels to WatchBlock Trade Flow - dars.gov.et
Immunic lines up three July investor events in Boston and SF - Stock Titan
abrdn discloses 6.05% Immunic (IMUX) stake held for clients - Stock Titan
Immunic posts updated corporate presentation under Regulation FD - TradingView
Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans - Stock Titan
Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus - Ad-hoc-news.de
Immunic announces participation in July investor conferences - Proactive financial news
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):